IDEX Q3 2026: Record Sales, Raised Guidance, and a $991M Order Book
As seen on the 24/7 Wall St. homepage on October 28, 2026.
AI power and semiconductor demand pushed the Health & Science Technologies segment up 14%, beating expectations on both lines and forcing a full-year adjusted EPS guidance raise. Orders of nearly $1 billion mean the visibility extends past this quarter.
Continue ReadingShow less
IDEX posted record quarterly revenue of $951.7 million in Q3 2026, with adjusted diluted EPS of $2.33 exceeding expectations. The detail underneath changes the forward calculus for investors.
The Health and Science Technologies segment was the standout, delivering 14% reported sales growth on surging AI-related demand in data center power and semiconductor markets, plus strength in space and defense, well ahead of the company's other segments. CEO Eric Ashleman noted that "momentum is broadening across the rest of the portfolio," so the growth extends beyond one segment.
IDEX booked $991.2 million in orders during the quarter, up 13% organically, giving management enough confidence to raise full-year 2026 guidance for the second time. The company now expects adjusted diluted EPS of $8.91 to $8.96, above prior guidance.
Sponsored
Margin execution held up even against persistent inflation: consolidated adjusted EBITDA margin expanded 50 basis points to 27.8%, supported by volume leverage and the company's 8020 operational methodology. Operating cash flow and free cash flow both grew, funding $129 million returned to shareholders through dividends and buybacks in the quarter.
Price and cost headwinds are still present, chemical, agriculture, and energy end markets remain soft, and tariff and trade policy uncertainty lingers. With a near-billion-dollar order book and a guidance range that implies another beat-and-raise quarter is already in the pipeline, those headwinds have so far proven manageable.
Mentioned: IEX